# Testing the Investigational Medication Pembrolizumab After Kidney Removal for Patients With Non-Clear Cell Renal Cell Carcinoma

> **NCT07689240** · PHASE3 · NOT_YET_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 400 (estimated)

## Conditions studied

- Non-Clear Cell Renal Cell Carcinoma
- Stage III Renal Cell Cancer AJCC v8
- Stage IV Renal Cell Cancer AJCC v8

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Scan
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Echocardiography Test
- **PROCEDURE:** Magnetic Resonance Imaging
- **OTHER:** Patient Observation
- **BIOLOGICAL:** Pembrolizumab
- **PROCEDURE:** Positron Emission Tomography

## Key facts

- **NCT ID:** NCT07689240
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-02-10
- **Primary completion:** 2032-01-01
- **Final completion:** 2032-01-01
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2026-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07689240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07689240, "Testing the Investigational Medication Pembrolizumab After Kidney Removal for Patients With Non-Clear Cell Renal Cell Carcinoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07689240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*